© 2006 European Society for Medical Oncology
symposium article |
Novel P53 mutations detected by FAMA in colorectal cancers
1 U.O. Medical Oncology, San Salvatore Hospital, University of L'Aquila; 2 Department of Surgery and Oncology, Medical Oncology Section, Università di Palermo; 3 U.O. Medical Oncology, University of Messina; 4 U.O. Medical Oncology, University of Chieti; 5 U.O. Clinical Pathology, University of Chieti, Italy
* Correspondence to: Dr E. Ricevuto, Università degli Studi di L'Aquila, Dipartimento di Medicina Sperimentale, Via Vetoio, Coppito II 67100, L'Aquila, Italia. Tel: 0862-433582; Fax: 0862-433523; E-mail: enrico.ricevuto{at}univaq.it
Background: The aim of the study was to identify p53 gene mutations by FAMA (fluorescence-assisted mismatch analysis) in colorectal cancers.
Patients and methods: Analytical scanning of the p53 gene (exons 5–9) was performed in colon cancer samples from 44 consecutive patients by FAMA. FAMA is a semiautomatic scanning approach based on the chemical cleavage of the mismatch in fluorescently labeled heteroduplex DNA, obtained from the combination of a normal and a mutated allele. FAMA has already shown optimal levels of diagnostic accuracy and sensitivity in detecting gene mutations (nucleotide substitutions, insertions/deletions) both at the germline and somatic level. The peculiar feature of FAMA is its ability to detect and localize mutations, by a redundant pattern of signals due to fluorescent DNA fragments generated by chemical cleavage. Moreover, previous data have demonstrated that normal contaminating DNA from stromal cells in the sample does not affect the sensitivity of the procedure, leading to the identification of the mutation even when the ratio mutant/normal allele is 10%.
Results: Eighteen mutations (12 missense, one nonsense, two deletions, three nucleotide substitutions at the level of the splice-junctions) and two polymorphisms were detected by FAMA in 17 patients (39%) and then confirmed by automated sequence analysis. Six of 18 mutations (33%) were not previously reported for colon cancer samples and two of 18 lesions (11%) were identified as novel p53 mutations.
Conclusions: Analytical scanning of the p53 gene by FAMA in DNA from colon cancer samples provides a sensitive, accurate and specific diagnostic procedure for routine clinical application.
Key words: colon cancer, p53, mutations, FAMA